Bristol-Myers Squibb Company (NYSE:BMY) does about 12.21M shares in volume on a normal day but saw 6377594 shares change hands in Friday trading. The company now has a market cap of 140.89B USD and an enterprise value of about $166.61B. Its current market price is $62.37, marking a decrease of -0.22% compared to the previous close of $62.51. The 52 week high reached by this stock is $68.34 whilst the lowest price level in 52 weeks is $45.76. The script in recent trading has seen the stock touch a high of $62.59 and a low of $61.85.
Bristol-Myers Squibb Company (BMY) has a 20-day trading average at $62.10 and the current price is -8.74% off the 52-week high compared with 36.30% distance from its 52-week low. The 50-day simple moving average of the closing price is $60.08 and its 200-day simple moving average is $60.47. If we look at the stock’s price movements over the week, volatility stands at 1.32%, which increases to 1.63% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 56.22 to suggest the stock is neutral.
15 analysts observing the Bristol-Myers Squibb Company (BMY) stock have set the 12-month price targets for the company’s shares at between $64.00 and $85.00. The consensus objective for the share price is $73.25, suggesting that the stock has a potential upside of 14.85% over the period. The median price target is 15.72% away from the current levels at $74.00.
FactSet Research has provided data showing that 15 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 2 advise that it is a overweight. 7 analysts have rated it as a buy and 6 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on July 28, 2020 when Raymond James initiated the stock to “Outperform” and issued a price target of $75. Morgan Stanley upgraded the stock to “Overweight” from Equal-Weight on April 02, 2020 at a price target of $64. Societe Generale downgraded its price target at $50.
The current price level is 0.73%, 4.03%, and 3.18% away from its SMA20, SMA50, and SMA200 respectively, with the BMY price moving above the 50-day SMA on August 28. Bristol-Myers Squibb Company (BMY) stock is up 0.29% over the week and 5.95% over the past month. Its price is -2.84% year-to-date and 29.21% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of $1.63 above consensus estimates by $0.15. BMY’s earnings per share are forecast to grow by 33.70% this year and 18.00% over next year. Expected sales for next quarter are $10.71 billion, which analysts say will come at $41.91 billion for the current fiscal year and next year at $45.42 billion. In addition, estimates put the company’s current quarterly revenue at an average of $10.31 billion.
Its 12-month price target is $74.00. To reach the target analysts have set, the stock logically needs to grow 14.85 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $64.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $85.00.
Outstanding shares total 2.26B with insiders holding 0.11% of the shares and institutional holders owning 79.09% of the company’s common stock. The company has a return on investment of 5.50% and return on equity of -1.30%. The forward price to earnings ratio is 8.42. The beta has a value of 0.68. Price to book ratio is 2.88 and price to sales ratio is 4.04.
According to a U.S. Securities and Exchange Commission filing, Vanguard Total Stock Market Index has reduced its position in Bristol-Myers Squibb Company (BMY) to 64,335,647 shares, mirroring a recent drop by -0.26%. Vanguard Total Stock Market Index dumped -0.17 million shares of Bristol-Myers Squibb Company common stock bringing its total worth to about $3.77 billion at the end of recent close, SEC documents show. Vanguard Total Stock Market Index isn’t the only investment manager who changed stakes and is followed by Vanguard 500 Index Fund, which sold off -0.28 million shares to end up with 46,662,316 shares worth $2.74 billion. Vanguard Health Care Fund cut their holdings by -5.22% in the company over the course of the most recent quarter. It now holds a 1.56% position in Bristol-Myers Squibb Company thanks to 35.18 million shares amounting to $2.06 billion.